The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1141
October 14, 2002
View Complete Issue         Table of Contents 2019 
Issue 1141
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Once-a-week Risedronate (Actonel)
October 14, 2002 (Issue: 1141)
A once-weekly 35-mg oral formulation of the bisphosphonate risedronate (Actonel) has been approved by the FDA for prevention and treatment of postmenopausal osteoporosis. A once-weekly formulation of alendronate (Fosamax) was approved last year...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1141
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.